Holen Sie sich die Stockscreener-App
0.5119
6.04%
-0.0329
Schlusskurs vom Vortag:
$0.5448
Offen:
$0.536
24-Stunden-Volumen:
746.26K
Relative Volume:
0.07
Marktkapitalisierung:
$25.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.02%
1M Leistung:
+44.73%
6M Leistung:
-33.52%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5084
$0.5499
1-Wochen-Bereich:
$0.5084
$0.5871
52-Wochen-Spanne:
$0.215
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
194 CANDELARO DRIVE, #233, HUMACAO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.5119 | 26.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Reports Final Results in Sublingual Aspirin Trial for Heart Attack Treatment; Shares Fall Pre Bell - MarketScreener
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - New Castle News
2-Minute Response Time: Aspire's New Sublingual Aspirin Could Revolutionize Heart Attack Treatment - Stock Titan
How to track smart money flows in Banc of California Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Weekly Investment Recap & Fast Moving Market Watchlists - Newser
How to track smart money flows in aTyr Pharma Inc.2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
ExlService Holdings Inc. stock chart pattern explainedTrade Exit Summary & Free Safe Entry Trade Signal Reports - Newser
Combining price and volume data for Shell plc Depositary ReceiptEarnings Risk Summary & Technical Buy Zone Confirmation - Newser
Aspire Biopharma Secures $9.7M Through Securities Agreement - MSN
How to track smart money flows in TTEC Holdings Inc.2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Historical volatility pattern of Zoomcar Holdings Inc. visualizedJuly 2025 Trends & Precise Swing Trade Entry Alerts - Newser
What earnings revisions data tells us about Newton Golf Company Inc.July 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Risk vs reward if holding onto Edesa Biotech Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
What MACD and RSI say about CHSNWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Aspire Biopharma enters $9.7 million note purchase agreement with investors By Investing.com - Investing.com Nigeria
Aspire Biopharma's Debt Refinancing: A Strategic Play for Biotech Capital Structure Optimization and Operational Flexibility - AInvest
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Promising Penny Stocks To Consider – August 18th - Defense World
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On?Aspire Biopharma Hldgs (NASDAQ:ASBP) - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
ASBP.O (Aspire Biopharma) Surges Over 80%: What's Driving the Intraday Spike? - AInvest
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Miami Herald
Aspire Biopharma to Present at Sidoti Virtual Investor Conference - AInvest
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
New Pre-Workout BUZZ BOMB Hits Market With Instant-Acting Sublingual Technology - Stock Titan
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Lubbock Avalanche-Journal
Riding the Waves: A Guide to Investing in ASBP Stock - investchronicle.com
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Es liegen keine Finanzdaten für Aspire Biopharma Holdings Inc (ASBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):